Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Efficacy of Oral BB102 Tablets in Patients With Advanced Solid Tumors

NCT06258408 is registered in ClinicalTrials.gov with Broadenbio Ltd., Co. as lead sponsor.

NCT NCT06258408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06258408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Efficacy of Oral BB102 Tablets in Patients With Advanced Solid Tumors
Lead sponsor
Broadenbio Ltd., Co.
Phase
Phase 1
Overall status
Recruiting
Start date
December 29, 2022
Completion date
December 31, 2026
Enrollment
78 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor